drugset / Trial / NCT01002625

A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

NCT01002625

Phase 1 Terminated 18 enrolled Pfizer
RandomizedCrossoverTriple-blindBasic science

Summary

PF-04457845 has been shown to temporarily decrease the dream (REM) period of sleep in rats, which suggests that PF-04457845 is active in rat's brains. This study is designed to see whether this is also the case in man.

Timeline

Start
2009-11
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject REDAFAMDASTAT Small molecule 4 mg

Indications

No indication recorded.